Skip to main content

Healthy Returns: Biotech IPOs ramped up to start 2024, but the market hasn't fully recovered just yet

Biotech IPOs surged at the start of 2024, but the rest of the year will depend on Fed rate cuts. Meanwhile, doctors using VR and AI to hone their skills.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.